This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Ariad Pharma Short Seller Explains Why Takeover Rumor Is Bunk

I spoke with an institutional investor this morning who's been shorting Ariad Pharmaceuticals (ARIA - Get Report), betting against the Daily Mail-fueled speculation of a takeover from Eli Lilly (LLY - Get Report) or any other Big Pharma suitor. 

"A takeover of Ariad by any Big Pharma would be career suicide for the business development guy proposing such a deal," this investor told me. He's not allowed to be quoted by name, per his fund's compliance rules. 

Why is the Ariad takeover speculation bunk? Because both of the Ariad drugs a potential suitor would be conceivably paying a premium for -- the chronic myeloid leukemia drug Iclusig and the ALK-inhibitor AP26113 -- are facing significant competition from drugs in Novartis' (NVS - Get Report) pipeline, he says.

Whatever value Iclusig and AP26113 have today stands a good chance of being erased if Novartis' drug development strategy pans out -- a risk not likely to be lost on Lilly or anyone else remotely considering an expensive Ariad acquisition. 

Here's his Ariad short thesis summarized:

Novartis is developing a third-generation BCR-ABL inhibitor known as ABL001 which works synergistically with Gleevec or Tasigna, the company's currently approved CML drugs. Novartis highlighted some preclinical data on ABL001 at an R&D event in November. Here's the slide:


If the combination of ABL001 and Tasignia prevents the emergence of resistance -- and can do so with a relatively clean safety profile -- there will be no room for Ariad's Iclusig, which is only approved right now for CML patients with the T315i mutation. 

Novartis is beginning human clinical trials of ABL001 in the first half of the year. 

Ariad's AP26113 faces a similar competitive threat from Novartis' own ALK inhibitor LDK378, which is already in phase III lung cancer studies, including patients no longer responsive to Pfizer's (PFE) original ALK inhibitor Xalkori. If LDK378 succeeds and is granted approval, Ariad's AP26113 isn't left with much room to maneuver in what is a relatively small commercial opportunity to begin with. 

Here's a slide from the same Novartis R&D day noting the pivotal studies of LDK378 in progress:

By the way, FDA granted Breakthrough Therapy designation to LDK378 last year. Ariad applied for same with AP26113 but was turned down. 

For these fundamental reasons, the chances Lilly or any other Big Pharma would pay a significant premium to acquire Ariad is very low, and therefore, the recent run in the value of the stock is unjustified and will disappear once the market realizes that no deal is forthcoming, this investor believes. 

-- Reported by Adam Feuerstein in Boston.  

Follow Adam Feuerstein on Twitter.

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.


Chart of I:DJI
DOW 17,773.64 -57.12 -0.32%
S&P 500 2,065.30 -10.51 -0.51%
NASDAQ 4,775.3580 -29.9330 -0.62%

Adam's Tweets

Select the service that is right for you!

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
Real Money Pro

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Trifecta Stocks

Trifecta Stocks analyzes over 4,000 equities weekly to find the elite 1% of stocks that pass rigorous quantitative, fundamental and technical tests.

Product Features:
  • Model portfolio
  • Trade alerts
  • Recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Growth Seeker

Chris Versace, using sophisticated stock screening and fundamental research, identifies potentially explosive small and mid-cap stocks.

Product Features:
  • Model portfolio
  • Small-cap and mid-cap focus
  • Intraday trade alerts
  • Weekly roundups
Daily Swing Trade

Master swing trader Alan Farley uses his sophisticated software screens to review thousands of stocks each day for you, to find just the handful that meet his demanding criteria.

Product Features:
  • Daily commentary and coaching on swing trading
  • Technical charts and analysis
Top Rated Stocks Top Rated Funds Top Rated ETFs